# Altered Chemotherapy Sequencing During Neoadjuvant Therapy for Patients With Stage II or III Rectal Adenocarcinoma

> **NCT01302613** · PHASE1,PHASE2 · WITHDRAWN · sponsor: **University of Texas Southwestern Medical Center**

## Conditions studied

- Stage II Rectal Cancer
- Stage III Rectal Cancer

## Interventions

- **DRUG:** Capecitabine
- **DRUG:** 5-FU
- **DRUG:** Leucovorin
- **DRUG:** Oxaliplatin
- **RADIATION:** radiation
- **PROCEDURE:** total mesorectal excision

## Key facts

- **NCT ID:** NCT01302613
- **Lead sponsor:** University of Texas Southwestern Medical Center
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2011-03
- **Primary completion:** 2012-11
- **Final completion:** 2012-11
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Drug shortage
- **Last updated:** 2020-08-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01302613

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01302613, "Altered Chemotherapy Sequencing During Neoadjuvant Therapy for Patients With Stage II or III Rectal Adenocarcinoma". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01302613. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*